At U.S. Medical Scientific Research Foundation, our strategy is to use our developmental compound library and strength in discovery and development to discover, and commercialize new drugs for severe medical conditions.
We believe U.S. Medical Scientific Research Foundation has a number of critical assets and capabilities that support our strategy and provide competitive advantages:
• Our unique biochemical compound library, the source of each of our pipeline drug candidates
• Our experience in innovative drug discovery that will lead to the discovery of first-in-class and best- in-class compound families
• Our capabilities in development, evidenced by our track record in designing, implementing, and conducting clinical trials and laboratory studies with EMODs
• Our focus on small-molecule drugs (EMODs), which have substantial advantages in patient convenience, safety and operating margins over injectable pharmaceutical drugs
We will continue to build on these strengths as we pursue our mission to extend and enhance the lives of severely ill patients. Disease prevention is equally important with disease control and cure.
To date U.S. Medical Scientific Research Foundation has maintained all rights to all of our products in all markets and indications. Going forward, partnerships with other pharmaceutical and medical device companies may play an important role in our growth. We expect to regularly evaluate partnership opportunities that enhance the overall value of our programs through a combination of complementary products or technologies, financial commitment, and commercial capabilities.
In addition to evaluating select strategic corporate partnership opportunities, we will strive to access leading-edge scientific R & D through our collaborations with researchers at top-tier academic institutions. U.S. Medical Scientific Research Foundation has formed numerous such alliances, and seeks outstanding collaborators for advancing the scientific understanding of our products and disease targets.
U.S. Medical Scientific Research Foundation places the utmost importance on protecting its intellectual assets and maintains a potential portfolio of domestic and foreign patents and patent applications.
Our patent estate currently is in the developmental phase, including compositions of matter, syntheses, and methods of use in the fields of cancer and autoimmune disease, as well as in other therapeutic areas within the organization’s focus. We will pursue exclusive licenses to several families of patent filings.
Our lead products are new chemical and biochemical entities that are structurally unique and will be well protected by composition of matter and method claims. Our intellectual property portfolio contains potential patent filings on novel excited state molecules and their targets and novel methods of utilization.